Weekly Investment Analysts’ Ratings Changes for Vericel (VCEL)

Several brokerages have updated their recommendations and price targets on shares of Vericel (NASDAQ: VCEL) in the last few weeks:

  • 1/15/2020 – Vericel was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $18.00 price target on the stock. According to Zacks, “Vericel Corporation is focused on developing patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. The company markets two autologous cell therapy products in the United States: Carticel (R) for the treatment of cartilage defects in the knee, and Epicel (R) for the treatment of severe burns. It is also developing MACI (TM) for the treatment of cartilage defects in the knee, and ixmyelocel-T for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy. Vericel Corporation, formerly Aastrom Biosciences, Inc., is based in United States. “
  • 1/11/2020 – Vericel was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. They now have a $19.00 price target on the stock. According to Zacks, “Vericel Corporation is focused on developing patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. The company markets two autologous cell therapy products in the United States: Carticel (R) for the treatment of cartilage defects in the knee, and Epicel (R) for the treatment of severe burns. It is also developing MACI (TM) for the treatment of cartilage defects in the knee, and ixmyelocel-T for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy. Vericel Corporation, formerly Aastrom Biosciences, Inc., is based in United States. “
  • 1/10/2020 – Vericel was downgraded by analysts at BidaskClub from a “sell” rating to a “strong sell” rating.
  • 1/3/2020 – Vericel was upgraded by analysts at ValuEngine from a “hold” rating to a “buy” rating.
  • 12/21/2019 – Vericel was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 12/13/2019 – Vericel was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.
  • 11/25/2019 – Vericel was upgraded by analysts at ValuEngine from a “hold” rating to a “buy” rating.

VCEL stock traded up $0.34 during midday trading on Thursday, hitting $17.28. 12,164 shares of the company’s stock were exchanged, compared to its average volume of 610,357. The business has a 50-day simple moving average of $17.68 and a two-hundred day simple moving average of $17.28. The company has a current ratio of 6.93, a quick ratio of 6.48 and a debt-to-equity ratio of 0.26. The stock has a market capitalization of $737.01 million, a PE ratio of -123.43 and a beta of 2.67. Vericel Corp has a 1-year low of $13.40 and a 1-year high of $21.00.

Vericel (NASDAQ:VCEL) last posted its earnings results on Tuesday, November 5th. The biotechnology company reported $0.07 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.02) by $0.09. The company had revenue of $30.50 million during the quarter, compared to analysts’ expectations of $26.84 million. Vericel had a positive return on equity of 3.66% and a negative net margin of 12.68%. The firm’s quarterly revenue was up 35.6% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.02) earnings per share. As a group, research analysts expect that Vericel Corp will post 0.16 EPS for the current fiscal year.

In other Vericel news, COO Michael Halpin sold 15,047 shares of the firm’s stock in a transaction on Monday, November 11th. The stock was sold at an average price of $18.53, for a total transaction of $278,820.91. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 4.50% of the stock is owned by company insiders.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. California Public Employees Retirement System boosted its position in shares of Vericel by 68.8% during the third quarter. California Public Employees Retirement System now owns 78,127 shares of the biotechnology company’s stock worth $1,183,000 after buying an additional 31,850 shares during the period. SG Americas Securities LLC purchased a new position in Vericel in the third quarter valued at $1,594,000. Boston Advisors LLC boosted its holdings in Vericel by 48.2% in the third quarter. Boston Advisors LLC now owns 69,411 shares of the biotechnology company’s stock valued at $1,051,000 after purchasing an additional 22,571 shares during the period. Russell Investments Group Ltd. boosted its holdings in Vericel by 3.2% in the third quarter. Russell Investments Group Ltd. now owns 460,942 shares of the biotechnology company’s stock valued at $6,976,000 after purchasing an additional 14,494 shares during the period. Finally, Granahan Investment Management Inc. MA boosted its holdings in Vericel by 9.1% in the third quarter. Granahan Investment Management Inc. MA now owns 280,774 shares of the biotechnology company’s stock valued at $4,251,000 after purchasing an additional 23,363 shares during the period. Institutional investors and hedge funds own 86.86% of the company’s stock.

Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, and distributes cellular therapies for sports medicine and severe burn care markets. It markets autologous cell therapy products, including MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of patients with deep-dermal or full-thickness burns.

Read More: How do candlesticks reflect price movement?

Receive News & Ratings for Vericel Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel Corp and related companies with MarketBeat.com's FREE daily email newsletter.